An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59–8862) in patients with taxane-resistant non-small cell lung cancer

Ortataxel is a novel second-generation taxane, with potent growth inhibitory activity against human cell lines that express P-glycoprotein 170

J. S. Gurtler

2017

Scholarcy highlights

  • Ortataxel is a novel second-generation taxane, with potent growth inhibitory activity against human cell lines that express P-glycoprotein 170
  • Taxane resistance was defined as PD during treatment or within 6 months of Rx with a prior taxane
  • Four investigator-confirmed partial responses to Ortataxel were documented in this trial so far
  • The study continues to enroll only pts with brain metastases in order to assess the drug in this subset of patients
  • ASCO.org ASCO Author Services ASCO Career Center CancerLinQ Conquer Cancer Foundation TAPUR Study

Need more features? Save interactive summary cards to your Scholarcy Library.